Literature DB >> 10652422

Regulation of telomerase by alternate splicing of human telomerase reverse transcriptase (hTERT) in normal and neoplastic ovary, endometrium and myometrium.

G A Ulaner1, J F Hu, T H Vu, H Oruganti, L C Giudice, A R Hoffman.   

Abstract

Telomerase extends telomeric repeats at the ends of linear chromosomes, thereby prolonging the replicative capacity of cells. To investigate possible regulatory mechanisms of telomerase, we measured telomerase enzyme activity, human telomerase RNA (hTR) and human telomerase reverse transcriptase (hTERT) mRNA in normal and neoplastic ovary, endometrium and myometrium. Telomerase activity was detected in most malignancies and in normal endometrium but not in myometrial leiomyoma, normal myometrium or normal ovary. hTR was expressed in all tissue samples. hTERT mRNA was expressed in many tissue samples, and no tissue sample exhibited telomerase activity without expressing hTERT mRNA. However, the presence of hTR and hTERT mRNA was not sufficient for telomerase activity. Alternate splicing of hTERT produced mRNAs lacking critical reverse transcriptase (RT) motifs in both normal and neoplastic tissues. Only tissues expressing hTERT containing complete A and B RT motifs demonstrated telomerase activity. Finally, several normal ovarian tissues and myometrial leiomyomas lacked telomerase activity despite expressing hTR and hTERT containing complete A and B RT motifs. This was not seen in ovarian and myometrial malignancies, where the expression of hTR and hTERT containing complete A and B RT motifs was sufficient for telomerase activity. We conclude that in ovarian and uterine tissues, the presence of a functional telomerase complex is regulated at multiple levels, including hTERT transcription and alternative splicing of hTERT transcripts. The lack of telomerase activity in several normal but not malignant tissues expressing hTR and hTERT containing complete A and B RT motifs suggests that there are further mechanisms for suppressing telomerase activity downstream of hTERT transcription and mRNA splicing, and these mechanisms have been lost during neoplastic transformation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10652422

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  36 in total

1.  The hTERTalpha splice variant is a dominant negative inhibitor of telomerase activity.

Authors:  L M Colgin; C Wilkinson; A Englezou; A Kilian; M O Robinson; R R Reddel
Journal:  Neoplasia       Date:  2000 Sep-Oct       Impact factor: 5.715

Review 2.  Natural and pharmacological regulation of telomerase.

Authors:  Jean-Louis Mergny; Jean-François Riou; Patrick Mailliet; Marie-Paule Teulade-Fichou; Eric Gilson
Journal:  Nucleic Acids Res       Date:  2002-02-15       Impact factor: 16.971

3.  Nuclear telomerase is less accessible to antibody probing than known nuclear antigens: retrieval with new immunostaining buffer.

Authors:  Danny Tze-Ming Leung; Chun-Hung Ma; Haitao Niu; Choong-Tsek Liew; Janet Tsui-Ying Tang; Pak-Leong Lim
Journal:  Histochem Cell Biol       Date:  2004-11-05       Impact factor: 4.304

4.  Differentiating alternative splice variant patterns of human telomerase reverse transcriptase in thyroid neoplasms.

Authors:  Yongchun Wang; Jeanne Kowalski; Hua-Ling Tsai; Radharani Marik; Nijaguna Prasad; Helina Somervell; Pang-Kuo Lo; Lauren E Sangenario; Lars Dyrskjot; Torben F Orntoft; William H Westra; Alan K Meeker; James R Eshleman; Christopher B Umbricht; Martha A Zeiger
Journal:  Thyroid       Date:  2008-10       Impact factor: 6.568

Review 5.  Human telomerase and its regulation.

Authors:  Yu-Sheng Cong; Woodring E Wright; Jerry W Shay
Journal:  Microbiol Mol Biol Rev       Date:  2002-09       Impact factor: 11.056

6.  Alternatively spliced telomerase reverse transcriptase variants lacking telomerase activity stimulate cell proliferation.

Authors:  Radmila Hrdlicková; Jirí Nehyba; Henry R Bose
Journal:  Mol Cell Biol       Date:  2012-08-20       Impact factor: 4.272

7.  Expression profile of a gamma-deletion variant of the human telomerase reverse transcriptase gene.

Authors:  Hisashi Hisatomi; Kazuma Ohyashiki; Junko H Ohyashiki; Kumi Nagao; Taichi Kanamaru; Hiroyuki Hirata; Nozomu Hibi; Yutaka Tsukada
Journal:  Neoplasia       Date:  2003 May-Jun       Impact factor: 5.715

8.  Significance of immunological detection of human telomerase reverse transcriptase: re-evaluation of expression and localization of human telomerase reverse transcriptase.

Authors:  Satoru Kyo; Kenkichi Masutomi; Yoshiko Maida; Taro Kanaya; Noriyuki Yatabe; Mitsuhiro Nakamura; Masaaki Tanaka; Mitsuko Takarada; Isamu Sugawara; Seishi Murakami; Takahiro Taira; Masaki Inoue
Journal:  Am J Pathol       Date:  2003-09       Impact factor: 4.307

9.  The major reverse transcriptase-incompetent splice variant of the human telomerase protein inhibits telomerase activity but protects from apoptosis.

Authors:  Imke Listerman; Jie Sun; Francesca S Gazzaniga; Jason L Lukas; Elizabeth H Blackburn
Journal:  Cancer Res       Date:  2013-04-22       Impact factor: 12.701

10.  Molecular cloning and characterization of the zebrafish (Danio rerio) telomerase catalytic subunit (telomerase reverse transcriptase, TERT).

Authors:  Benson Wui-Man Lau; Anderson On-Lam Wong; George Sai-Wah Tsao; Kwok-Fai So; Henry Ka-Fun Yip
Journal:  J Mol Neurosci       Date:  2007-09-19       Impact factor: 3.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.